Humacyte Inc. (NASDAQ:HUMA) stock plunged Thursday despite reporting positive interim Phase 3 data for its acellular tissue-engineered vessel (ATEV), as investors focused on a heavily dilutive stock offering announced alongside the clinical update.
On Wednesday, Humacyte released interim Phase 3 results for its acellular tissue-engineered vessel (ATEV) in female dialysis patients.
ATEV is a bioengineered human tissue derived from cultured human cells that is designed to be a universally implantable vascular conduit for use in vascular replacement and repair.
Phase 3 Trial Meets Primary Endpoint
The biotechnology company said a prespecified interim analysis of the first 80 patients enrolled in its Phase 3 V012 study met the trial’s primary endpoint.
